Posted by Michael Wonder on 20 Jun 2022
Givlaari is included in the high-cost protection with limitation
17 June 2022 - Givlaari (givosiran) is included in the high-cost protection with limited subsidy to reduce attacks in patients with acute hepatic porphyria in adults and adolescents from 12 years of age.
TLV has had tripartite discussions with the company and the regions. Within the framework of these deliberations, the company and the regions have signed a side agreement for Givlaari which means that the treatment costs for Givlaari are reduced. This side agreement is part of TLV's decision basis.
